FGI-104
FGI-104 is an investigational antiviral compound that has shown potential in the treatment of various viral infections. It is primarily studied for its efficacy against filoviruses, such as Ebola virus and Marburg virus.
Mechanism of Action[edit | edit source]
FGI-104 functions by inhibiting the entry of viruses into host cells. It targets the viral glycoproteins that are essential for the fusion of the viral envelope with the host cell membrane. By blocking this critical step, FGI-104 prevents the virus from replicating within the host.
Pharmacokinetics[edit | edit source]
The pharmacokinetic profile of FGI-104 is still under investigation. Preliminary studies suggest that it has a moderate half-life, allowing for potential once-daily dosing. The compound is believed to be metabolized in the liver, with renal excretion of its metabolites.
Clinical Trials[edit | edit source]
FGI-104 is currently undergoing clinical trials to evaluate its safety and efficacy. Early-phase trials have demonstrated promising results in terms of reducing viral load and improving survival rates in animal models. Human trials are in the early stages, focusing on safety and dosage optimization.
Potential Applications[edit | edit source]
FGI-104 is being explored for use in outbreaks of Ebola virus disease and Marburg virus disease. Its broad-spectrum antiviral activity also suggests potential applications against other RNA viruses.
Safety and Side Effects[edit | edit source]
As with any investigational drug, the safety profile of FGI-104 is not fully established. Common side effects observed in early trials include mild gastrointestinal disturbances and transient liver enzyme elevations. Long-term safety data are not yet available.
Research and Development[edit | edit source]
FGI-104 is being developed by a consortium of researchers and pharmaceutical companies. The development process involves collaboration with governmental and non-governmental organizations to expedite the availability of the drug in response to viral outbreaks.
See Also[edit | edit source]
Drugs for HIV Infection, in the Subclass Antiretroviral Agents
- Fusion Inhibitors (HIV)
- Integrase Inhibitors (HIV)
- Nonnucleoside Reverse Transcriptase Inhibitors (HIV)
- Nucleoside Analogues (HIV)
- Protease Inhibitors (HIV)
HCV NS5A Inhibitors
HCV NS5B Inhibitors (Polymerase inhibitors)
- Asunaprevir, Boceprevir, Glecaprevir, Grazoprevir, Paritaprevir, Simeprevir, Telaprevir, Voxilaprevir
Combination Therapies
Drugs for Herpes Virus
- infections (HSV), CMV, others
Acyclovir, Cidofovir, Famciclovir, Foscarnet, Ganciclovir, Valacyclovir, Valganciclovir
Drugs for Influenza
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD